Healthcare
RedHill Biopharma Ltd.(RDHL)
Live Price
Offline$0.814
+3.69% today
1Y Change
-57.14%
Window
Jun 23, 2025 β Jun 12, 2026
- Market Cap
- β
- Revenue Growth
- -96.4%
- EPS Growth
- +100.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars Β· Jun 23, 2025 β Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RedHill Biopharma Ltd. (RDHL) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.81 and down 57.1% across the available one-year price window (Jun 23, 2025 β Jun 12, 2026). Baseline metrics include revenue growth of -96.4%, EPS growth of +100.0%, a dividend yield of 0.0%. What stands out right now is revenue -96.4%, EPS +100.0%, free cash flow -3.0% with operating margin -109.5% and ROIC -118.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RDHL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-96.4% vs +7.6% peer median
Operating Margin
Below sector median
-109.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 9, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -96.4% and EPS is at +100.0%, with operating margin around -109.5%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 13, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 9, 2026 | β | -0.7% | -5.5% | +21.5% |
2026 Mar 30, 2026 | β | +0.0% | +7.4% | +39.6% |
2025 Sep 5, 2025 | β | +0.4% | +5.3% | +32.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RDHL
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
RDHL Max Drawdown
-70.44%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RDHL and SPY.
Company Overview
RedHill Biopharma Ltd.
NASDAQ Global Market
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
- Leadership
- Dror Ben-Asher
- IPO Date
- Jan 7, 2013
- Employees
- 35
- Street Address
- 21 Haβarbaβa Street
- Mailing
- Tel Aviv, 6473921
- Region
- Tel Aviv, IL
- Reporting Currency
- USD
- Investor Line
- 972 3 541 3131
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 0.5
- Price/Book
- 0.5
Growth
- Revenue
- -96.4%
- EPS
- +100.0%
- Free Cash Flow
- -3.0%
Profitability
- Gross Margin
- 63.3%
- Operating Margin
- -109.5%
- Net Margin
- -98.7%
- ROE
- 291.1%
- ROIC
- -118.5%
Balance Sheet
- Debt/Equity
- 0.25
- Current Ratio
- 0.34
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.